Solventum Corp (SOLV)
SubavaliadaFundamental
64
Preço
$86.85
Capitalização de Mercado
$15.24B
Parte 1 · Quanto vale a empresa
Visão Geral
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$8.31B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$1.43B
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$-10M
Capital Próprio Total
$5.05B
Passivo Total
$9.24B
Rácio de Liquidez
1.02
Cobertura de Juros
-
Dívida/EBITDA
1.98
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$126.13
Preço Atual
$86.85
Margem de Segurança
+31.1%
Intervalo de Valor Justo
$81.98 - $170.27
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
10.76
ROE
30.8%
Rácio P/B
3.13
P/FCF
-
Margem Bruta
54.7%
ROIC
15.5%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
15.5%
WACC
6.3%
ROIC − WACC
+9.2 pp
O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.
Critérios de Análise Fundamental
Aprovado (15)
- EPS shows upward trend
- Price CAGR 15.07%
- ROIC 15.5%
- Gross Margin 54.7%
- Debt/Equity ratio
- Operating Margin 25.0%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 29.0%
- Analyst Consensus 59% Buy
- Earnings Surprise avg 11.0%
- Share Dilution 1.0%
- Net Margin Trend 17.3% vs 4.5%
- Piotroski F-Score 7/9
Reprovado (7)
- EPS CAGR 4.51%
- P/B Ratio 3.13
- Positive Free Cash Flow
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- Earnings Quality (OCF/NI) 0.15
Indisponível (6)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
Número de ações estável
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Bryan C. Hanson | CEO & Director | 58 |
| Mr. Wayde D. McMillan | Executive VP & CFO | 55 |
| Ms. Amy Landucci | Chief Information & Digital Officer | 50 |
| Ms. Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary | 58 |
| Ms. Heather L. Knight | Chief Commercial Officer | 53 |
| Mr. Neil C. Zieselman | Senior VP, Controller & Chief Accounting Officer | 49 |
| Ms. Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications | - |
| Ms. Kate Dobbs | Chief Communications & Corporate Marketing Officer | - |
| Ms. Rachel H. Ellingson | Chief Strategy & Corporate Development Officer | 55 |
| Ms. Tammy L. Gomez | Chief Human Resources Officer | 52 |
Risco de Auditoria
10
Risco do Conselho
3
Risco de Remuneração
8
Risco dos Direitos dos Acionistas
6
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-27
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-05
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-08-05
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for SOLV, sourced from Markets Gazette.
- 2/26/2026NEUTRALSolventum (SOLV) Q4 2025 Earnings Call Transcript
The transcript for Solventum Corporation's (SOLV) fourth-quarter 2025 earnings call has been made available, marking a routine event in the company's financial calendar. Solventum, a healthcare technology spin-off from 3M, is under investor scrutiny for its performance post-separation. While the release of the transcript is a standard step for transparency, the absence of the actual earnings content prevents an in-depth analysis. Investors are awaiting the detailed financial figures and future outlook to assess the business trajectory and potential implications for share value. Currently, the mere availability of the transcript, without the underlying data, provides no clear directional guidance for the market.
via Markets Gazette